Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
…, P Tesson, F Braye, C Naltet, P Lavaud… - Clinical Cancer …, 2020 - AACR
Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated …
inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated …
[HTML][HTML] Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
P Lavaud, F Andre - BMC medicine, 2014 - Springer
Breast cancers over-express the human epidermal growth factor receptor 2 (HER2) in about
15% of patients. This transmembrane tyrosine kinase receptor activates downstream …
15% of patients. This transmembrane tyrosine kinase receptor activates downstream …
Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations
Importance DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant
prostate cancer (CRPC), and some of these aberrations have been associated with …
prostate cancer (CRPC), and some of these aberrations have been associated with …
[HTML][HTML] Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression
…, K Howarth, JC Benitez, A Gazzah, P Lavaud… - Journal of Thoracic …, 2020 - Elsevier
Introduction In patients with oncogene-addicted NSCLC and isolated central nervous system
progression (iCNS), tissue biopsy is challenging, and the clinical utility of plasma liquid …
progression (iCNS), tissue biopsy is challenging, and the clinical utility of plasma liquid …
[HTML][HTML] Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Background Prostate cancer is one of the most common cancers in men and the fourth leading
cause of cancer mortality worldwide. Although major progress has been achieved in the …
cause of cancer mortality worldwide. Although major progress has been achieved in the …
Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for …
P Lavaud, G Gravis, S Foulon, F Joly, S Oudard… - European Urology, 2018 - Elsevier
Background Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit
men with metastatic castration-naive prostate cancer (mCNPC) following results from …
men with metastatic castration-naive prostate cancer (mCNPC) following results from …
[HTML][HTML] Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint …
…, L El-Amarti, L Hendriks, R Ferrara, C Naltet, P Lavaud… - Cancers, 2020 - mdpi.com
Simple Summary Recently, the introduction of immunotherapy radically changed the
therapeutic algorithm of non-small-cell lung cancer as an upfront or secondary strategy. …
therapeutic algorithm of non-small-cell lung cancer as an upfront or secondary strategy. …
Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer
…, N van Dijk, GVO de Rueda, A Necchi, P Lavaud… - European urology, 2020 - Elsevier
Background Immune checkpoint inhibitors (ICIs) are approved for first-line (cisplatin unfit, PD-L1+)
and platinum-refractory urothelial carcinoma (UC). Still, most patients experience …
and platinum-refractory urothelial carcinoma (UC). Still, most patients experience …
PARP inhibition, a new therapeutic avenue in patients with prostate cancer
Up to 25% of patients with metastatic prostate cancer present with germline or somatic DNA
damage repair alterations, some of which are associated with aggressive disease and poor …
damage repair alterations, some of which are associated with aggressive disease and poor …
[HTML][HTML] Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
…, A Aberlenc, L Mezquita, Y Lecluse, P Lavaud… - NPJ Precision …, 2021 - nature.com
Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic
Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are …
Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are …